Justin Y. K. Tang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tang_Justin_MD_420x504.jpg

First Name

Justin

Last Name

Tang

NPI

1619385747

Faculty ID

16500

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

56697

Is Open Scheduling

Off

Yvonne M. Saenger

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/5da83a20-2f18-11ed-9b6c-217aa43c9197.jpg

First Name

Yvonne

Last Name

Saenger

NPI

1235363664

Faculty ID

17090

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yvonne Saenger is an expert in cancer immunotherapy with a focus on melanoma and gastro-intestinal tumors</p>
<p>The Saenger laboratory researches immune biomarkers for melanoma recurrence to stratify patients for adjuvant immunotherapy.&nbsp; Digital pathology and artificial intelligence methods are used.</p>
<p>A second area of focus is analysis of the tumor immune micro-environment in liver cancer, particularly on studying human specimens and organoids to define the role of immune cell populations and complement in tumor progression.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Gartrell-Corrado RD, Chen A, Rizk EM , Marks DK, Bogardus M, Hart TD, Silverman AM, Bayan CA, Finkel G, Barker L , Komatsubara KM, Carvajal RD, Horst BA, Chang R, Monod A , Rabad&aacute;n R, <strong>Saenger Y</strong>, &ldquo;Linking transcriptomic and imaging data </span><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma,&rdquo; <em>Cancer Research.</em> 2020 Mar 1;80(5):1078-1087. PMID:&nbsp;31948941</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Kulkarni PM, Robinson EJ, Pradhan JS, Gartrell-Corrado RD, Rohr B, Kluger HM, Wong PF, Acs B, Rizk EM, Yanc C, Mondal M, Moore M, Phelps R, Hoorst BA, Ferringer T, Rimm DL, Wang J, <strong>Saenger Y</strong>, &ldquo;Deep learning based on standard H&amp;E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death,&rdquo; <em>Clinical Cancer Research</em></span><span style="font-size: 14pt; font-family: Calibri, sans-serif;">. 2019 Oct 21. <em>Clinical Cancer Research</em>.1495.2019. PMID: 31636101</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gerard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst B, <strong>Saenger YM, &ldquo;</strong></span><strong><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma,&rdquo;</span></strong> <strong><em><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">Clinical Cancer Research</span></em></strong><strong><em><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">, </span></em></strong><strong><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">2019 Jan 15</span></strong> <span style="font-size: 14pt; font-family: Calibri, sans-serif;">PMID: 30647081</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Zhao J, Chen AX, Gartrell RD, Silverman A, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Goetz M, Yagamuchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yun J, Canoll P, Bruce JN, <strong>Saenger YM</strong>, Sims P, Iwamoto FB, Sonabend AM, Rabadan, R. &ldquo;Longitudinal genomic study of response to anti-PD-1 immunotherapy in Glioblastoma Multiforme<em>,&rdquo; Nature Medicine 2019 </em>Mar 25(3):462-469 PMID: 30742119</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, <strong>Saenger YM, &ldquo;</strong>Quantitative Analysis of Immune Infiltrates in Primary Melanoma,&rdquo;<span class="jrnl"> <em>Cancer Immunol Res</em></span><em>.</em> 2018 <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Apr;6(4):481-493</span> PMID: 29467127</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">&nbsp;</span></span></p>
<p class="desc" style="margin: 0in 2pt 0in 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE, Perni S, Weisberg SP, Rizk EM, Wang S, Oh EJ, Guo XV, Chiuzan C, Manji GA, Bates SE, Chabot J, Schrope B, Kluger M, Emond J, Rabad&aacute;n R, Farber D, Remotti HE, Horowitz </span></span><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">DP,&nbsp;<strong>Saenger YM. </strong></span></span><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma, <span class="docsum-journal-citation">Oncoimmunology. 2022 May 5. PMID: </span><span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">35558160</span></span></p>
<p>&nbsp;</p>
<p>&nbsp;</p>

EMR ID

116437

Is Open Scheduling

Off

Nitin Ohri

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4a5e97b0-c3cc-11eb-a1b3-af964b18991d.jpg

First Name

Nitin

Last Name

Ohri

NPI

1346499431

Faculty ID

13388

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treating lung and gastrointestinal cancers.

Research Focus

Incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy.

Elsevier Profile

EMR ID

5629

Biography

<p>Nitin Ohri, MD, MS, is Professor, Radiation Oncology at Montefiore Einstein. He is a radiation oncologist with a clinical focus on treating lung and gastrointestinal cancers.</p><p>After completing his Bachelor of Science in biomedical engineering at Columbia University in 2003, Dr. Ohri earned his Doctor of Medicine from Washington University in 2007. He then completed an internship in internal medicine at Barnes-Jewish Hospital in 2008 and then participated in a radiation oncology residency at Thomas Jefferson University, completing it in 2012. Dr. Ohri earned his Master's degree from the Clinical Research Training Program at Montefiore Einstein in 2015.</p><p>Building on his clinical focus, Dr. Ohri&rsquo;s research focuses on incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy. Dr. Ohri has designed numerous ongoing and completed investigator-initiated trials that test novel functional imaging-based radiotherapy delivery strategies and new combinations of immunotherapy and radiotherapy. He is also leading a series of trials incorporating continuous activity monitoring with wearable devices into the care of cancer patients. The unifying theme of his work is leveraging novel forms of multidimensional data to improve cancer care, and his work has been presented in many peer-reviewed publications and abstracts. Dr. Ohri is a reviewer for multiple journals, such as the <em>International Journal of Radiation Oncology, Biology, Physics</em>, the <em>American Journal of Clinical Oncology</em> and <em>Journal of the National Cancer Institute</em>.</p><p>Dr. Ohri is board certified in Radiation Oncology by the American Board of Radiology and is a member of the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Association for Cancer Research. He has won multiple awards, including numerous &ldquo;Outstanding Reviewer&rdquo; Awards from the <em>International Journal of Radiation Oncology, Biology, Physics</em>, the Cancer Care Delivery Research Pilot Project Award from NRG Oncology and the Fellowship Award from the Empire Clinical Research Investigator Program.</p>

Is Open Scheduling

Off

Keyur J. Mehta

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mehta_Keyur_MD_420x504-2.jpg

First Name

Keyur

Last Name

Mehta

NPI

1235339326

Faculty ID

12249

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4466

Is Open Scheduling

Off

Beth N. McLellan

https://assets.montefioreeinstein.org/profiles/images/physphoto/McLellan_Beth_MD_LC_420x504.jpg

First Name

Beth

Last Name

McLellan

NPI

1356512412

Faculty ID

14084

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Beth McLellan graduated with honors from Northwestern University and attended medical school at Wayne State University where she graduated with Alpha Omega Alpha honors. She completed an internship in Internal Medicine at Loyola University Health System and her Dermatology residency at Henry Ford Health System in Detroit where she also served as Chief Resident. She currently is a Professor in the Department of Medicine (Dermatology) and has served as Chief of the Division of Dermatology since 2020.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan specializes in complex medical Dermatology and has a special interest in Supportive Oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair, and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis as well as successful use of bacterial decolonization for prevention of radiation dermatitis. She has published numerous articles and textbook chapters related to Supportive Oncodermatology and is regularly invited to speak at Dermatology and Oncology conferences for physicians and patients including the annual meeting of the American Academy of Dermatology, ASCO, and Gilda's Club.</span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Playing an active role in the Dermatology Residency, Dr. McLellan is the director of resident research and regularly lectures residents and medical students. She has served as a mentor to many residents and students and directs a year-long Oncodermatology research fellowship for medical students taking a year off for research.&nbsp; Interested medical students can learn more about the fellowship here: https://www.einsteinmed.edu/departments/medicine/divisions/dermatology/…;
<div>&nbsp;</div>
<div>&nbsp;</div>
<div>&nbsp;</div>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. McLellan specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.

Research Focus

Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis

Elsevier Profile

Selected Publications

<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1-KCbcoWaApUyh/bibliography/5…;

EMR ID

5777

Biography

<p>Beth N. McLellan, MD, is Chief, Dermatology, Director, Supportive Oncodermatology and Professor, Dermatology at Montefiore Einstein. She specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</p><p>After earning her Doctor of Medicine at Wayne State University, Dr. McLellan completed an internship in internal medicine at Loyola University Health System and her dermatology residency at Henry Ford Health System where she also served as chief resident and initiated a supportive oncodermatology clinic. Dr. McLellan received additional oncodermatology training at Memorial Sloan Kettering Cancer Center and at the Institut Gustave Roussy in Paris, France.</p><p>Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis. Playing an active role in the Montefiore Einstein Dermatology Residency, Dr. McLellan is the Director of Resident Research and regularly lectures residents and medical students at both dermatology and oncology meetings. She has served as a mentor to many residents and students and directs a year long oncodermatology research fellowship for medical students taking a year off for research. Dr. McLellan has published numerous articles and textbook chapters related to supportive oncodermatology and is regularly invited to speak at dermatology and oncology conferences for physicians and patients, including the annual meeting of the American Academy of Dermatology, American Society of Clinical Oncology and Gilda's Club.</p><p>As part of her commitment to treating the whole patient, Dr. McLellan founded the New York Vitiligo Support Group. She has received awards from the Dermatology Foundation.</p>

Is Open Scheduling

On

Jana L. Fox

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f6b22b70-d525-11eb-af57-a79c115e5bbd.jpg

First Name

Jana

Last Name

Fox

NPI

1154467363

Faculty ID

13179

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5426

Is Open Scheduling

Off

David H. Ciocon

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/1f99b570-35c5-11ed-8123-8ffce84a9f6a.jpg

First Name

David

Last Name

Ciocon

NPI

1790878866

Faculty ID

12226

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. David Ciocon received his undergraduate degree from Harvard University (cum laude with HIgh Honors in History and Literature) and his M.D. from UMDNJ-New Jersey Medical School, where he was elected to the Alpha Omega Alpha Honor Society. Prior to his residency in dermatology, he completed three years of a combined general and plastic surgery residency training at Brown University, Rhode Island Hospital as well as a one-year clinical research fellowship in psoriasis at Harvard University, Brigham &amp; Women's Hospital. He subsequently completed a dermatology residency at the Albert Einstein College of Medicine, Montefiore Medical Center, where he was Chief Resident and recipient of the Leo M. Davidoff Award for Excellence in Teaching. He then completed a Mohs Micrographic Surgery and Procedural Dermatology fellowship at Skin Laser &amp; Surgery Specialists of New York and New Jersey under the guidance of Dr. David Goldberg in 2009.&nbsp;</p>
<p>Since 2013, Dr. Ciocon has served as the Director of Dermatologic Surgery, Mohs Micrographic Surgery and Procedural Dermatology at the Montefiore Medical Center, Albert Einstein College of Medicine. He has also serves as the Director of Clinical Operations of the Dermatology Division of the Montefiore Medical Center.&nbsp;</p>
<p>Dr. Ciocon is a member of the American Society for Dermatologic Surgery, the American Academy of Dermatology, and the American College of Mohs Surgery. He serves on the Editorial Board of the Journal of Cosmestic and Laser Therapy. He is a preceptor in the American Society of Dermatologic Surgery Preceptor program.</p>
<p>Dr. Ciocon's clinical interests include Mohs Micrographic surgery, facial reconstructive and aesthetic surgery, laser-assisted tumescent liposuction, autologous fat transfer, laser medicine, and minimally invasive cosmetic dermatology. He has written multiple peer-reviewed publications and textbooks with respect to surgical and non-surgical approaches to cutaneous oncology, cutaneous reconstruction, and aesthetic rejuvenation.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Lab Website Link

Selected Publications

<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">Soliman YS, Mieczkowska K, Zhu TR, Hossain O, Zhu TH, <strong>Ciocon DH</strong>, Williams RF. Characterizing basal cell carcinoma in Hispanic individuals undergoing Mohs micrographic surgery: a 7-year retrospective review at an academic institution in the Bronx. Br J Dermatol. 2022 Oct;187(4):597-599.</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">&nbsp;</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">Williams RF, <strong>Ciocon DH.</strong> Mohs Micrographic Surgery in Skin of Color. J Drugs Dermatol. 2022 May 1;21(5):536-541.</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">&nbsp;</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">Dautriche-Svidzinski CN, Manning J, Williams RF<strong>, Ciocon DH</strong>. Treatment algorithm for basal cell carcinoma of the external auditory canal. Dermatol Surg. 2022 Mar 1;48(3):372-373.</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">&nbsp;</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">Soliman YS, Mieczkowska K, Zhu TR, Hossain O, &nbsp;Zhu TH, <strong>Ciocon DH</strong>, Williams RF. Keratinocyte carcinoma resected by Mohs micrographic surgery in individuals with skin of color: An observational study. J Am Acad Dermatol. 2023 May;88(5):1183-1185.</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;">&nbsp;</h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">Hoffman L, Benesh G, Soliman Y,&nbsp;<strong>Ciocon D</strong>, Williams R<span style="color: #212121; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">. </span>Diversifying the Mohs Workforce: Understanding Barriers of Applicants to Mohs Micrographic Surgery Fellowship. J Drugs Dermatol. 2023 May 1;22(5):471-474.</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">&nbsp;</span></h2>
<h2 class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">Nazarian R, Manning J, <strong>Ciocon DH</strong>. Repair of a nasal tip defect. </span>Dermatol Surg. 2023 Sep 1;49(9):889-891.</h2>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;">&nbsp;</p>

EMR ID

4822

Biography

<p>David Ciocon, MD, is Director, Mohs Micrographic Surgery and Procedural Dermatology and Director, Clinical Operations, Dermatology Division at Montefiore Einstein and Associate Professor, Dermatology at our Albert Einstein College of Medicine. Dr. Ciocon&rsquo;s clinical focus centers on Mohs micrographic surgery, cutaneous oncology, cosmetic dermatologic surgery and lasers.</p><p>After obtaining his Bachelor of Arts from Harvard University in 1994, Dr. Ciocon earned his Doctor of Medicine at Rutgers University in 2002. He completed an internship and residency in general and plastic surgery at Brown University, Rhode Island Hospital in 2005 and became a dermatopharmacology research fellow at Harvard University, Brigham and Women's Hospital until 2006. Following this, Dr. Ciocon completed his dermatology residency at Albert Einstein College of Medicine in 2009, where he was Chief Resident in his final year. He then completed a Mohs micrographic surgery and procedural dermatology fellowship at Skin Laser & Surgery Specialists of New York and New Jersey in 2010.</p><p>Building on his clinical focus, Dr. Ciocon&rsquo;s research is focused on Mohs micrographic surgery, dermatologic oncology, cosmetic dermatologic surgery and lasers. His work has been published in numerous peer-reviewed journals, books, book chapters and abstracts. He has also given many national presentations.</p><p>Dr. Ciocon is board certified by the American Board of Dermatology with a subspecialty certification in Micrographic Dermatologic Surgery. He is a member of several professional organizations, including the American Medical Association, the American Academy of Dermatology and the American Society of Dermatologic Surgery, among others. In 2009, Dr. Ciocon received the Leo M. Davidoff Award for Excellence in Teaching. He has been named "Top Doctor" in both <em>New York Magazine</em> and <em>Westchester Magazine</em>, as well as "Top Doctor, New York City Metro Area" by Castle Connolly for multiple consecutive years.</p>

Is Open Scheduling

Off